Industry Updates From the Field of Stem Cell Research and Regenerative Medicine in November 2020

Ilić, Duško; Liović, Mirjana

doi:10.2217/rme-2020-0208

Cited by 2 publications

(2 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 88 ] Another unique feature of Matrion is that during rehydration it doesn't get folded or rolled up, thus having fewer chances of migration away from the injury site. [ 89 ] A current trial is underway to examine the safety and efficacy of Matrion in managing diabetic foot ulcers and lower extremity wounds. The trial involves 120 participants aged 21–80 years who have full‐thickness wounds due to Type I or Type II diabetes.…”

Section: Commercial Products For Chronic Wounds Treatmentmentioning

confidence: 99%

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Sharma

Zhao

2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Impaired wound healing after trauma, disorders, and surgeries impact millions of people globally every year. Dysregulation in orchestrated healing mechanisms and underlying medical complications make chronic wound management extremely challenging. Besides standard‐of‐care treatments including broad spectrum antibiotics and wound‐debridement, novel adjuvant therapies are clinically tested and commercialized. These include topical agents, skin substitutes, growth factor delivery, and stem cell therapies. With a goal to overcome factors playing pivotal role in delayed wound healing, researchers are exploring novel approaches to elicit desirable healing outcomes in chronic wounds. Although recent innovations in wound care products, therapies, and devices are extensively reviewed in past, a comprehensive review summarizing their clinical outcomes is surprisingly lacking. Herein, this work reviews the commercially available wound care products and their performance in clinical trials to provide a statistically comprehensive understanding of their safety and efficacy. The performance and suitability of various commercial wound care platforms, including xenogeneic and allogenic products, wound care devices, and novel biomaterials, are discussed for chronic wounds. The current clinical evaluation will provide a comprehensive understanding of the benefits and drawbacks of the most‐recent approaches and will enable researchers and healthcare providers to develop next‐generation technologies for chronic wound management.

show abstract

Section: Commercial Products For Chronic Wounds Treatmentmentioning

confidence: 99%

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Sharma

Zhao

2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Similarly, a randomised controlled clinical trial investigating UC-MSCs reported improved survival rate, reduced length of stay and ventilator use as well as a decrease in IL-6 in patients who received UC-MSCs in COVID-19 ARDS (NCT04457609) [ 36 ]. Moreover, Mesoblast have reported positive initial findings from their phase 3 randomised, double-blind, placebo-controlled trial investigating Remestemcel-L in COVID-19 ARDS at international conferences (NCT04371393) [ 37 ]. Importantly, the work from Calfee and colleagues and others supports the idea of identifying phenotypes of ARDS [ 38 , 39 ] or treatable traits [ 40 ] and using that information to facilitate a personalised medicine approach.…”

Section: The Progress In the Clinical Translation Of Mscs For Inflammatory Lung Diseasementioning

confidence: 99%

The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Dunbar

Weiss

Enes

et al. 2021

Cells

View full text Add to dashboard Cite

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better understand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.

show abstract

Industry Updates From the Field of Stem Cell Research and Regenerative Medicine in November 2020

Abstract: Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in November 2020.

Cited by 2 publications

References 3 publications

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Contact Info

Product

Resources

About